Vivus tumbles on concerns about generic Qsymia
News | 17 August 2012
NEW YORK (AP) ? Shares of Vivus Inc. stumbled Friday after an analyst slashed his sales estimates for Vivus' new obesity drug Qsymia, saying many physicians may prescribe Qsymia's ingredients for their patients instead of the drug itself. THE SPARK: ...
Click on the link to read the full article at Businessweek
(This link will open in a new window)
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
